---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-085432"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2026-08-05T13:27:18+00:00"
generated_at: "2026-08-05T13:28:08.587138+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology: new institutional accounts ordering LYMPHIR up 78% QoQ

## Summary
- New institutions ordering LYMPHIR increased 78% in Q2 2026 vs. prior quarter; total vial orders up 31%.
- LYMPHIR now available in 42 institutions including academic and NCCN centers.
- Near-universal payer coverage achieved; initial CTCL market exceeds $400 million.
- Company expects >20 additional institutions in current quarter, targeting 100 priority institutions by year-end.
- Wholesaler reorders have begun reflecting increased institutional demand; revenue recognized on filled wholesale orders.

## SEC filing metadata
- accession: 0001213900-26-085432
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2026-08-05T13:27:18+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390026085432/0001213900-26-085432-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390026085432/ea0300373-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-085432
- JSON: https://secwatch.observer/filing/0001213900-26-085432.json
- Plain text: https://secwatch.observer/filing/0001213900-26-085432.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.